Your local office
We are looking for the closest office..

QbD Group has acquired EUDRAC

Dusseldorf/Antwerp – CFI is pleased to announce it acted as exclusive financial advisor to QbD Group, a leading life science services provider, on the acquisition of regulatory affairs and pharmacovigilance specialist EUDRAC.

The QbD Group, a privately held company offering comprehensive support to life science companies throughout the entire product lifecycle, today announced the acquisition of EUDRAC Ltd., a specialist regulatory and pharmacovigilance consultancy.

EUDRAC Ltd. provides a bespoke consultancy service throughout product development, regulatory approval, market launch, and into life cycle management. Their success is built upon strong relationships with EMA and MHRA and experience across a wide range of therapeutic areas, pharmaceutical forms, and an in-depth knowledge of legislation and guidance.

Joining the QbD Group will allow EUDRAC Ltd. access to a broader client base and the infrastructure necessary to ensure continued growth. EUDRAC Ltd. will be renamed as QbD Ltd.

In turn, this acquisition will expand the QbD Group’s regulatory affairs division to better serve its pharmaceutical customers, including those developing advanced therapy medicinal products (ATMPs).

Carole Pugh, Managing Director of EUDRAC Ltd. said:

“We’re delighted to bring our expertise into the QbD group. This is the right time for us to make this step and will allow us to benefit from the synergies the acquisition will bring. In addition to bringing opportunities for business growth it will give our team of experts opportunities to develop their knowledge and skills.”

Bart Van Acker, founder and CEO of QbD, added:

“The QbD Group is continuously expanding our already broad ecosystem through strategic alliances and acquisitions. The addition of EUDRAC Ltd. takes us yet another step closer to our QbDream of offering a comprehensive range of skills and expertise to support product development throughout the life sciences.”

CFI acted as the exclusive financial advisor to QbD’s management and shareholders in a structured buy-side process to identify the ideal partner, including preparing business valuations, coordinating the due diligence process and transaction negotiations.

Tom Lokermans, CFO of QbD, commented:

“CFI managed to introduce us to the founder of this really interesting company which we were now able to convert into a member of the QbD Group. They always managed all initial meetings with the founder and guided and assisted us through the rest of the process, from valuation, due diligence to closing. During the process, CFI developed a good understanding of our strategic requirements. We therefore are grateful that we had CFI on our side.”

This transaction closed on 7 November 2022.


Healthcare & Life Sciences

has acquired

Advised by:

Similar Transactions